Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biopharmaceutical company based in Sarasota, Florida, dedicated to the discovery and development of a novel class of anti-infective agents. The company's proprietary technology platform, known as Bisphosphocins™, consists of synthetic, small-molecule compounds designed to address the growing global threat of multi-drug resistant (MDR) bacterial, viral, and fungal infections. Unlike traditional antibiotics that often target specific metabolic pathways, Bisphosphocins utilize a unique mechanism of action that rapidly disrupts the bacterial cell membrane. This physical mode of action makes it significantly more difficult for pathogens to develop resistance, offering a potential breakthrough for patients who have exhausted conventional treatment options. The company's lead product candidate, Nu-3, is being developed as a topical and systemic antimicrobial. It has been studied for the treatment of infected diabetic foot ulcers and other chronic wounds where biofilm and resistant bacteria are prevalent. Beyond wound care, Lakewood-Amedex is exploring the application of its platform for respiratory tract infections and other systemic indications. The company aims to leverage its intellectual property and clinical data to form strategic partnerships and advance its pipeline through the regulatory approval process to meet the urgent need for effective new anti-infectives.